Chi­nese health au­thor­i­ty erects new gold stan­dard in on­col­o­gy R&D, spook­ing in­vestors in boom­ing field

The US has long been the leader in re­search and de­vel­op­ment in on­col­o­gy, but home­grown Chi­nese drug­mak­ers have jumped one hur­dle af­ter an­oth­er in mak­ing a name for them­selves. Now, the Chi­nese gov­ern­ment is erect­ing new hur­dles for its na­tive in­dus­try to leap, and — at least for now — it’s putting a slight chill on the field.

The Chi­nese health au­thor­i­ty NM­PA’s Cen­ter for Drug Eval­u­a­tion re­leased new guid­ance on on­col­o­gy R&D late last week, of­fer­ing a new gold stan­dard for how home­grown drug­mak­ers should de­ter­mine clin­i­cal ef­fi­ca­cy amid a boom­ing field for drug in­no­va­tion, ac­cord­ing to draft doc­u­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER